title: 17beta-estradiol inhibits prostaglandin E2-induced COX-2 expressions and cell migration by suppressing Akt and ERK1/2 signaling pathways in human LoVo colon cancer cells.
abstract: Epidemiological studies demonstrate that the incidence and mortality rates of colorectal cancer in women are lower than in men. However, it is unknown if 17beta-estradiol treatment is sufficient to inhibit prostaglandin E2 (PGE2)-induced cellular motility in human colon cancer cells. Upregulation of cyclooxygenase-2 (COX-2) is reported to associate with the development of cancer cell mobility, metastasis, and subsequent malignant tumor. After administration of inhibitors including LY294002 (Akt activation inhibitor), U0126 (ERK1/2 inhibitor), SB203580 (p38 MAPK inhibitor), SP600125 (JNK1/2 inhibitor), or QNZ (NFkappaB inhibitor), we found that PGE2 treatment increases COX-2 via Akt and ERK1/2 pathways, thus promoting cellular motility in human LoVo cancer cells. We further observed that 17beta-estradiol treatment inhibits PGE2-induced COX-2 expression and cellular motility via suppressing activation of Akt and ERK1/2 in human LoVo cancer cells. Collectively, these results suggest that 17beta-estradiol treatment dramatically inhibits PGE2-induced progression of human LoVo colon cancer cells.
authors.affiliation: College of Chinese Medicine, School of Post-Baccalaureate Chinese Medicine, China Medical University, Taichung, Taiwan.
authors.forename: Tung-Yuan
authors.initials: TY
authors.lastname: Lai
authors.forename: Li-Mien
authors.initials: LM
authors.lastname: Chen
authors.forename: Jing-Ying
authors.initials: JY
authors.lastname: Lin
authors.forename: Bor-Show
authors.initials: BS
authors.lastname: Tzang
authors.forename: James A
authors.initials: JA
authors.lastname: Lin
authors.forename: Chang-Hai
authors.initials: CH
authors.lastname: Tsai
authors.forename: Yueh-Min
authors.initials: YM
authors.lastname: Lin
authors.forename: Chih-Yang
authors.initials: CY
authors.lastname: Huang
authors.forename: Chung-Jung
authors.initials: CJ
authors.lastname: Liu
authors.forename: Hsi-Hsien
authors.initials: HH
authors.lastname: Hsu
mesh_terms: D002465:Cell Movement / Q000187:drug effects*; D003110:Colonic Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D051546:Cyclooxygenase 2 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D015232:Dinoprostone / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology*; D006801:Humans; D015151:Immunoblotting; D019950:Mitogen-Activated Protein Kinase 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D048052:Mitogen-Activated Protein Kinase 3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D014407:Tumor Cells, Cultured
chemical_list: D004958:Estradiol; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D051057:Proto-Oncogene Proteins c-akt; D019950:Mitogen-Activated Protein Kinase 1; D048052:Mitogen-Activated Protein Kinase 3; D015232:Dinoprostone
references.citation: J Natl Cancer Inst. 1995 Apr 5;87(7):517-23
references.pmid: 7707438
references.citation: N Engl J Med. 2004 Mar 4;350(10):991-1004
references.pmid: 14999111
references.citation: Annu Rev Biochem. 2000;69:145-82
references.pmid: 10966456
references.citation: J Natl Cancer Inst. 2002 Feb 20;94(4):252-66
references.pmid: 11854387
references.citation: CA Cancer J Clin. 2002 Jan-Feb;52(1):23-47
references.pmid: 11814064
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: Cancer Res. 2002 May 1;62(9):2522-30
references.pmid: 11980644
references.citation: N Engl J Med. 2000 Jun 29;342(26):1946-52
references.pmid: 10874062
references.citation: Am J Med. 1998 Mar 30;104(3A):2S-8S; discussion 21S-22S
references.pmid: 9572314
references.citation: FEBS Lett. 2008 Oct 15;582(23-24):3415-22
references.pmid: 18789327
references.citation: Ann Intern Med. 1998 May 1;128(9):705-12
references.pmid: 9556463
references.citation: Cancer Res. 2007 May 1;67(9):4320-7
references.pmid: 17483345
references.citation: J Pharmacol Exp Ther. 2008 Dec;327(3):863-71
references.pmid: 18784349
references.citation: Srp Arh Celok Lek. 2008 Mar-Apr;136(3-4):187-92
references.pmid: 18720757
references.citation: Cancer Sci. 2008 Nov;99(11):2120-7
references.pmid: 18823380
references.citation: Chem Biol. 1996 Jul;3(7):529-36
references.pmid: 8807884
references.citation: Gastroenterology. 1994 Oct;107(4):1183-8
references.pmid: 7926468
references.citation: Neoplasia. 2000 Nov-Dec;2(6):523-30
references.pmid: 11228545
references.citation: CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
references.pmid: 14974761
references.citation: Curr Genomics. 2006;7(8):497-508
references.pmid: 18369406
references.citation: J Biol Chem. 1998 Jan 23;273(4):2424-8
references.pmid: 9442092
references.citation: Mol Cancer Ther. 2004 Aug;3(8):1031-9
references.pmid: 15299086
references.citation: Cancer. 1992 Sep 1;70(5 Suppl):1206-15
references.pmid: 1511368
references.citation: Cell. 1996 Nov 29;87(5):803-9
references.pmid: 8945508
references.citation: Cancer Res. 2001 Feb 15;61(4):1733-40
references.pmid: 11245490
references.citation: Best Pract Res Clin Endocrinol Metab. 2003 Mar;17(1):139-47
references.pmid: 12763517
references.citation: Cancer Res. 2001 Jan 15;61(2):632-40
references.pmid: 11212261
references.citation: J Biol Chem. 2000 May 19;275(20):14838-45
references.pmid: 10809726
references.citation: J Nutr Biochem. 2009 Sep;20(9):663-76
references.pmid: 18824345
references.citation: J Clin Invest. 1997 May 1;99(9):2254-9
references.pmid: 9151799
references.citation: J Clin Gastroenterol. 2007 Sep;41(8):731-46
references.pmid: 17700421
references.citation: Int Immunopharmacol. 2008 Dec 20;8(13-14):1821-6
references.pmid: 18801463
references.citation: Trends Pharmacol Sci. 2003 Feb;24(2):96-102
references.pmid: 12559775